PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.


Journal

International immunology
ISSN: 1460-2377
Titre abrégé: Int Immunol
Pays: England
ID NLM: 8916182

Informations de publication

Date de publication:
30 05 2020
Historique:
received: 21 12 2019
accepted: 01 02 2020
pubmed: 6 2 2020
medline: 2 1 2021
entrez: 4 2 2020
Statut: ppublish

Résumé

Persistent exposure to tumor antigens results in exhausted tumor-infiltrating T cells (TILs) that express the immune checkpoint molecules, PD-1 and Tim3, and lack anti-tumor immunity. To examine the exhausted status of TILs in ovarian cancer, the potential for cytokine production, proliferation and cytotoxicity by purified PD-1+ Tim3+ CD8 TILs was assessed. The production of IFN-γ and TNF-α by PD-1+ Tim3+ CD8 TILs remained the same in an intracellular cytokine staining assay and was higher in a cytokine catch assay than that by PD-1- Tim3- and PD-1+ Tim3- CD8 TILs. %Ki67+ was higher in PD-1+ Tim3+ CD8 TILs than in PD-1- Tim3- CD8 TILs. However, patients with high PD-1+ Tim3+ CD8 TILs had a poor prognosis. The potential for cytotoxicity was then examined. %Perforin+ and %granzyme B+ were lower in PD-1+ Tim3+ CD8 TILs than in PD-1- Tim3- and PD-1+ Tim3- CD8 TILs. To observe the potential for direct cytotoxicity by T cells, a target cell line expressing membrane-bound anti-CD3scFv was newly established and a cytotoxic assay targeting these cells was performed. The cytotoxicity of PD-1+ Tim3+ CD8 TILs was significantly lower than that of PD-1- Tim3- and PD-1+ Tim3- CD8 TILs. Even though PD-1+ Tim3+ CD8 TILs in ovarian cancer showed a sustained potential for cytokine production and proliferation, cytotoxicity was markedly impaired, which may contribute to the poor prognosis of patients with ovarian cancer. Among the impaired functions of exhausted TILs, cytotoxicity may be an essential target for cancer immunotherapy.

Identifiants

pubmed: 32009163
pii: 5721204
doi: 10.1093/intimm/dxaa010
doi:

Substances chimiques

HAVCR2 protein, human 0
Hepatitis A Virus Cellular Receptor 2 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

397-405

Informations de copyright

© The Japanese Society for Immunology. 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Masaaki Sawada (M)

Department of Clinical Research in Tumor Immunology, Osaka, Japan.
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.

Kumiko Goto (K)

Department of Clinical Research in Tumor Immunology, Osaka, Japan.
Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Toyonaka, Japan.

Akiko Morimoto-Okazawa (A)

Department of Clinical Research in Tumor Immunology, Osaka, Japan.
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.

Miya Haruna (M)

Department of Clinical Research in Tumor Immunology, Osaka, Japan.
Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Toyonaka, Japan.

Kei Yamamoto (K)

Department of Clinical Research in Tumor Immunology, Osaka, Japan.

Yoko Yamamoto (Y)

Department of Clinical Research in Tumor Immunology, Osaka, Japan.

Satoshi Nakagawa (S)

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.

Kosuke Hiramatsu (K)

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.

Shinya Matsuzaki (S)

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.

Eiji Kobayashi (E)

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.

Atsunari Kawashima (A)

Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.

Michinari Hirata (M)

Department of Clinical Research in Tumor Immunology, Osaka, Japan.
Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Toyonaka, Japan.

Kota Iwahori (K)

Department of Clinical Research in Tumor Immunology, Osaka, Japan.

Toshihiro Kimura (T)

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.

Yutaka Ueda (Y)

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.

Tadashi Kimura (T)

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.

Hisashi Wada (H)

Department of Clinical Research in Tumor Immunology, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH